16 completed, 4 recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4, 1 Early Phase 1.
Follow Dalfampridine: new trials by email Literature Review of Dalfampridine trials Research Report on Dalfampridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma 4-Aminopyridine - Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy | Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 50 | 2026-12-01 | 2026-09-21 |
| Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Imatinib, Fampridine - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | University of California, San Diego | 18 | 2026-05-13 | 2026-05-27 |
| 4-Aminopyridine to Treat Skin Burns Drug: 4-Aminopyridine, Placebo - Burns, Second Degree Burn | Phase 2 | Recruiting | John Elfar | 200 | 2026-01-01 | 2026-03-05 |
| Double Dose 4-AP on Functional Recovery After Spinal Cord Injury Dalfampridine, Placebo, STDP stimulation - SCI - Spinal Cord Injury | Phase 1 / Phase 2 | Recruiting | Shirley Ryan AbilityLab | 27 | 2025-02-01 | 2026-06-03 |
| Effects of 4-AP on Functional SCI Recovery Dalfampridine, Placebo drug, STDP stimulation - Spinal Cord Injury | Early Phase 1 | Completed | Shirley Ryan AbilityLab | 26 | 2022-06-30 | 2026-06-03 |
| 4-aminopyridine Treatment for Nerve Injury 4-Aminopyridine, Placebo - Nerve Injury, Prostate Cancer | Phase 2 / Phase 3 | Recruiting | John Elfar | 70 | 2021-06-05 | 2025-12-17 |
| Use of Dalfampridine in Primary Lateral Sclerosis dalfampridine - Motor Neuron Disease, Upper | Phase 1 | Completed | Hospital for Special Surgery, New York | 26 | 2016-03-01 | 2026-10-13 |
| Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults Placebo, Dalfampridine - Sleep Apnea, Obstructive | Phase 2 | Completed | Brigham and Women's Hospital | 13 | 2016-01-01 | 2017-08-15 |
| Fampridine Pregnancy Exposure Registry Fampridine - Multiple Sclerosis, Pregnancy | Terminated | Biogen | 1 | 2015-08-01 | 2016-10-18 | |
| Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis Dalfampridine, Placebo - Multiple Sclerosis, Internuclear Ophthalmoplegia | Phase 2 | Completed | VA Office of Research and Development | 23 | 2015-04-01 | 2020-09-04 |
| Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis fampridine, Placebo - Multiple Sclerosis | Phase 3 | Completed | Biogen | 646 | 2014-09-01 | 2017-03-27 |
| Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Dalfampridine, Placebo - Transverse Myelitis, Neuromyelitis Optica | Phase 2 | Completed | Johns Hopkins University | 24 | 2014-02-01 | 2018-04-17 |
| A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Placebo, BIIB041 (fampridine) - Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive | Phase 3 | Completed | Biogen | 101 | 2013-08-01 | 2017-03-21 |
| A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) dalfampridine, Placebo - Non Arteritic Ischemic Optic Neuropathy | Phase 4 | Completed | Neuro-Ophthalmologic Associates, PC | 20 | 2013-07-01 | 2016-01-25 |
| Dalfampridine and Gait in Spinocerebellar Ataxias Dalfampridine, Placebo - Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2 | Not applicable | Completed | University of Florida | 20 | 2013-02-01 | 2015-01-12 |
| Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury Dalfampridine, Placebo - Spinal Cord Injury | Phase 2 | Completed | Kessler Foundation | 27 | 2012-06-01 | 2017-12-02 |
| An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice Fampridine - Multiple Sclerosis | Completed | Biogen | 4734 | 2012-04-16 | 2019-06-05 | |
| Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Fampridine - Multiple Sclerosis | Phase 4 | Completed | Biogen | 901 | 2012-02-01 | 2017-03-21 |
| Effects of Dalfampridine on Cognition in Multiple Sclerosis dalfampridine, placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | State University of New York at Buffalo | 61 | 2011-12-01 | 2020-10-01 |
| Dalfampridine for Imbalance in Multiple Sclerosis Dalfampridine, Placebo - Multiple Sclerosis, Fatigue | Phase 2 | Completed | Oregon Health and Science University | 24 | 2011-09-01 | 2014-06-16 |
Showing 20 of 22. Sign in to see all of them.
Multiple Sclerosis (9) · Spinal Cord Injuries (3) · Fatigue (2) · Burns (1) · Erectile Dysfunction (1) · Gastrointestinal Stromal Tumors (1) · Motor Neuron Disease (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Myelitis (1) · Myelitis, Transverse (1) · Neuromyelitis Optica (1) · Ocular Motility Disorders (1) · Optic Neuropathy, Ischemic (1) · Prostatic Neoplasms (1)
Biogen (7) · John Elfar (2) · Shirley Ryan AbilityLab (2) · Brigham and Women's Hospital (1) · Hospital for Special Surgery, New York (1) · Johns Hopkins University (1) · Kessler Foundation (1) · Milton S. Hershey Medical Center (1) · Neuro-Ophthalmologic Associates, PC (1) · Oregon Health and Science University (1) · State University of New York at Buffalo (1) · University of California, San Diego (1) · University of Florida (1) · VA Office of Research and Development (1)
United States (15) · France (3) · Netherlands (3) · Australia (2) · Canada (2) · Czechia (2) · Germany (2) · Italy (2) · Portugal (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · Denmark (1) · Finland (1)
John Elfar, MD (2) · Alessandro Serra, MD PhD (1) · Bianca Weinstock-Guttman, MD (1) · Dale Lange, MD (1) · Gail F. Forrest, Ph.D. (1) · Guangbin Xia, MD, PhD (1) · John P Gniady, MD (1) · Mark L Moster, MD (1) · Michael Levy, MD, PhD (1) · Monica A Perez, PT, PhD (1) · Monica Perez, PT, PhD (1) · Paul Fanta, MD (1) · Ralph Benedict, PhD (1) · Rashid Sayyid, MD (1)
PMID 28387543, PMID 30535670, PMID 30566030, PMID 34322853, PMID 38773595
1IK2RX001180-01A2 (1), R35NS122336 (1)